Evidence map›Paper›PMID 36066585›Full record

ArticleEuropean journal of trauma and emergency surgery : official publication of the European Trauma Society2023

COVID-19 rapid molecular point-of-care testing is effective and cost-beneficial for the acute care of trauma patients.

Josef Stolberg-Stolberg, Elena Jacob, Joachim Kuehn, Marc Hennies, Wali Hafezi, Moritz Freistuehler, Jeanette Koeppe, Alex W Friedrich, J Christoph Katthagen, Michael J Raschke

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of trauma and emergency surgery : official publication of the European Trauma Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Josef Stolberg-StolbergDepartment of Trauma, Hand and Reconstructive Surgery, University Hospital Muenster, Albert-Schweitzer-Campus 1, Building W1, 48149, Muenster, Germany. Josef.Stolberg-Stolberg@ukmuenster.de.
Elena JacobDepartment of Trauma, Hand and Reconstructive Surgery, University Hospital Muenster, Albert-Schweitzer-Campus 1, Building W1, 48149, Muenster, Germany.
Joachim KuehnDepartment of Clinical Virology, Institute of Virology, University Hospital Muenster, 48149, Muenster, Germany.
Marc HenniesDepartment of Clinical Virology, Institute of Virology, University Hospital Muenster, 48149, Muenster, Germany.
Wali HafeziDepartment of Clinical Virology, Institute of Virology, University Hospital Muenster, 48149, Muenster, Germany.
Moritz FreistuehlerMedical Management Division-Medical Controlling, University Hospital Muenster, Niels-Stensen-Straße 8, 48149, Muenster, Germany.
Jeanette KoeppeInstitute of Biostatistics and Clinical Research, University of Muenster, Schmeddingstrasse 56, 48149, Muenster, Germany.
Alex W FriedrichMedical Executive Board, University Hospital Muenster, Albert-Schweitzer-Campus 1, Building D5, 48149, Muenster, Germany.
J Christoph KatthagenDepartment of Trauma, Hand and Reconstructive Surgery, University Hospital Muenster, Albert-Schweitzer-Campus 1, Building W1, 48149, Muenster, Germany.
Michael J RaschkeDepartment of Trauma, Hand and Reconstructive Surgery, University Hospital Muenster, Albert-Schweitzer-Campus 1, Building W1, 48149, Muenster, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the accuracy and cost benefit of a rapid molecular point-of-care testing (POCT) device detecting COVID-19 within a traumatological emergency department.

backgroundDespite continuous withdrawal of COVID-19 restrictions, hospitals will remain particularly vulnerable to local outbreaks which is reflected by a higher institution-specific basic reproduction rate. Patients admitted to the emergency department with unknown COVID-19 infection status due to a- or oligosymptomatic COVID-19 infection put other patients and health care workers at risk, while fast diagnosis and treatment is necessary. Delayed testing results in additional costs to the health care system.

methodsFrom the 8th of April 2021 until 31st of December 2021, all patients admitted to the emergency department were tested with routine RT-PCR and rapid molecular POCT device (Abbott ID NOW™ COVID-19). COVID-19-related additional costs for patients admitted via shock room or emergency department were calculated based on internal cost allocations.

results1133 rapid molecular tests resulted in a sensitivity of 83.3% (95% CI 35.9-99.6%), specificity of 99.8% (95% CI 99.4-100%), a positive predictive value of 71.4% (95% CI 29-96.3%) and a negative predictive value of 99.9% (95% CI 99.5-100%) as compared to RT-PCR. Without rapid COVID-19 testing, each emergency department and shock room admission with subsequent surgery showed additional direct costs of 2631.25€, without surgery of 729.01€.

conclusionAlthough rapid molecular COVID-19 testing can initially be more expensive than RT-PCR, subsequent cost savings, improved workflows and workforce protection outweigh this effect by far. The data of this study support the use of a rapid molecular POCT device in a traumatological emergency department.

Indexed as

COVID-19COVID-19 TestingHumansPoint-of-Care SystemsPoint-of-Care TestingSensitivity and SpecificityCOVID-19Emergency medicineID NOWRapid molecular point-of care testingTraumatology

Identifiers

PMID36066585
PMCPMC9447950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.